Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Yersinia pestis

- PMLiVE

Nektar Therapeutics announces top-line results from alopecia areata study

This autoimmune disease causes hair loss in both women and men, affecting 160 million people worldwide

- PMLiVE

Sanofi and Owkin expand AI collaboration to include drug positioning in immunology

The expansion builds on the companies’ strategic alliance previously announced in 2021

- PMLiVE

Pfizer’s Litfulo approved by EC for adults and adolescents with severe alopecia areata

The autoimmune disease affects approximately 147 million people globally

- PMLiVE

Genomics England receives government funding for cutting-edge genomics research

£105m will be used to accelerate the diagnosis of rare genetic diseases in newborns

- PMLiVE

BioNTech and Ryvu partner to develop immuno-modulatory small molecule candidates

The focus will be on immune modulation within oncology and potentially other disease areas

- PMLiVE

GSK’s new global survey exposes lupus treatment gaps

The findings show opportunities to address organ damage risk for early stage lupus patients

- PMLiVE

Sanofi’s Enjaymo receives EC approval for rare autoimmune haemolytic anaemia

Cold agglutinin disease affects around 12,000 people in the US, Europe and Japan

- PMLiVE

New study links genetic traits of Black Death survivors and autoimmune diseases today

The study involved the extraction and screening of more than 500 ancient DNA samples

- PMLiVE

Amgen completes acquisition of ChemoCentryx in deal worth $3.7bn

Amgen gains access to the biopharma’s autoimmune disease treatment Tavneos

- PMLiVE

Incyte to acquire Villaris Therapeutics to expand inflammation and autoimmunity portfolio

Auremolimab, which has proven efficacy for vitiligo, is included in the deal

- PMLiVE

The imperfect art of sustainable communications

Scanning the papers this last week, we’ve seen a welcome departure from wall-to-wall gloom –and very real signs of ‘Reasons To Be Cheerful’.The economy, we’re told, might not be such...

11 London

- PMLiVE

Merck to acquire Pandion Therapeutics for $1.85bn

Merck will gain a pipeline of immune modulators targeting autoimmune diseases

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links